CND Life Sciences, Inc.
Scottsdale, AZ
- UEI
- N8BNGXXEBP75
- CAGE
- 7WHZ5
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 9165 E Del Camino Dr suite 101, Scottsdale, AZ 85258, USA
- Website
- cndlifesciences.com
- Founded
- 2017
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $54,518 |
| FY2025 | $85,650 |
| FY2024 | $0 |
| FY2023 | $5,636 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $54,518 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Synone esoteric testing services | Veterans Integrated Service Network 10 (VHA) | $140,168 | |
| UC187 FY22 - SYN-one testing | Medical Command (Army) | $5,636 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Amprion, Inc. | San Francisco, CA | 621511 Medical Laboratories |
| Neurodex Inc. | Natick, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Athena Diagnostics, Inc. | Marlborough, MA | 621511 Medical Laboratories |
| Aivocode, Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Amydis, Inc. | San Diego, CA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
CND Life Sciences, Inc. is a for-profit corporate entity headquartered in Scottsdale, Arizona, specializing in diagnostic testing services for neurodegenerative diseases. The company has developed the SYN-ONE Test, a minimally invasive diagnostic technology designed to detect phosphorylated alpha-synuclein proteins associated with various neurological conditions. Through federal contract and grant awards, CND Life Sciences provides esoteric testing services and conducts advanced medical research focused on identifying and understanding neurodegenerative disease progression.
Regarding federal contract awards, CND Life Sciences has received two notable purchase orders. The first, valued at $85,650, was awarded by the Veterans Integrated Service Network 10 (VISN 10) for SYN-ONE esoteric testing services to be performed at their Scottsdale facility from August 15, 2025 through August 14, 2026. The second contract, worth $5,636, was issued by the Defense Health Agency on September 25, 2023, also for SYN-ONE testing. Both contracts were standard purchase orders with no specific set-aside designations, indicating the company's capability to provide specialized medical testing services directly to federal agencies.
In terms of federal grant awards, CND Life Sciences has secured multiple substantial grants from the National Institutes of Health, specifically from the National Institute of Neurological Disorders and Stroke and the National Institute on Aging. These grants, totaling over $1.2 million, support advanced research into neurodegenerative diseases. One $1,276,662 grant aims to develop a diagnostic test to identify patients with Essential Tremor who may progress to Parkinson's Disease. Another grant focuses on detecting phosphorylated alpha-synuclein in patients with Idiopathic Rapid Eye Movement Sleep Behavior Disorder, seeking to predict potential synucleinopathy phenoconversion. A third grant, awarded by the National Institute on Aging, seeks to validate a diagnostic test for distinguishing between Dementia with Lewy Bodies and Alzheimer's Disease, highlighting the company's commitment to advanced neurological diagnostic research.
SBA capabilities narrative
We are testing labratory for the medical field testing for Neurodegenerative diseases. The top 5 disease we typically test for include Parkinson's disease (PD)
Dementia with Lewy bodies (DLB)
Multiple system atrophy (MSA)
Pure autonomic failure (PAF)
REM sleep behavior disorder (RBD)
Quick answers
Is CND Life Sciences, Inc. registered in SAM.gov?
Yes. CND Life Sciences, Inc.'s SAM.gov registration is active through June 18, 2027.
What is CND Life Sciences, Inc.'s CAGE code?
CND Life Sciences, Inc.'s CAGE code is 7WHZ5, and its Unique Entity ID (UEI) is N8BNGXXEBP75.
How much has CND Life Sciences, Inc. received in federal contracts?
Federal contracts obligated $85,650 to CND Life Sciences, Inc. in fiscal year 2025 and $145,804 in fiscal years 2023 through 2027.
What is CND Life Sciences, Inc.'s most recent federal award?
CND Life Sciences, Inc.'s most recent federal grant award is Analysis of cutaneous phosphorylated alpha-synuclein to identify patients at risk of progressing from essential… (R44NS143486), from National Institute of Neurological Disorders and Stroke (NIH), on September 5, 2025.
On GovTribe
See CND Life Sciences, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors